ngµç×ÓÓÎÏ·

05

¿ÆÑÐÏ£Íû

лÏþÑࡢ˧ÐÄÌÎÍŶӽÒÏþÖ×ÁöÃâÒßÖÎÁÆÐÂЧ¹û

¸å¼þȪԴ£º£º£ºÁ¥ÊôµÚÒ»Ò½Ôº ±à¼­£º£º£ºÖ£Áú·É¡¢Íõ¶¬Ã· ÔĶÁÁ¿£º£º£º

ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±¹ù»ÀÁᣩ¿ËÈÕ£¬£¬ngµç×ÓÓÎÏ·Á¥ÊôµÚÒ»Ò½Ôº³¬Éùҽѧ¿ÆÐ»ÏþÑà½ÌÊÚÍŶÓÓëngµç×ÓÓÎÏ·ÖÊÁÏ¿ÆÑ§Ó빤³ÌѧԺ˧ÐÄÌνÌÊÚÍŶӵĽ»Ö¯Ñ§¿ÆÏàÖúÑо¿Ð§¹ûÔÚ¸ßÖÊÁ¿ÔÓÖ¾Nano TodayÉÏÒÔresearch articleµÄÐÎʽ½ÒÏþ¡£¡£ ¸ÃÑо¿ÎªÒÔPD-1/PD-L1Ϊ°ÐµãµÄRFAºóÖ×Áö×ÛºÏÖÎÁÆÌṩÁËÀíÂÛÒÀ¾Ý£¬£¬ÎªÊÜÀ§ÓÚÃâÒßÒ©ÎïÄÍÒ©ºÍ¶¾¸±×÷ÓõÄÖ×Áö»¼Õß´øÀ´ÁËеÄÏ£Íû£¬£¬¶Ô¸ÄÉÆÖ×ÁöRFAÊõºóÔ¤ºó¾ßÓÐDZÔÚµÄÁÙ´²¼ÛÖµ¡£¡£

É䯵ÏûÈÚ£¨Radiofrequency ablation, RFA£©ÒòÆä΢´´¡¢ÁÆÐ§È·ÇС¢×¡ÔºÊ±¼ä¶ÌµÈÓÅÊÆ£¬£¬ÒÑ¿ªÕ¹ÎªÖ×Áö×ÛºÏÖÎÁƵÄÖ÷Òª×é³É²¿·Ö£¬£¬ÆÕ±éÓ¦ÓÃÓÚÔ­·¢»òÕß×ªÒÆÐÔ¸ÎÔàÖ×ÁöµÈʵÌåÖ×ÁöµÄÖÎÁÆ¡£¡£¿ÉÊÇ£¬£¬¹ØÓÚÖ×ÁöÖ±¾¶´óÓÚ3 cm¡¢ÐÎ̬²»¹æÔò¡¢Î»ÓÚÖ÷ÒªÔàÆ÷¼°´óѪ¹ÜÅÔµÄÖ×Áö£¬£¬RFAÍùÍùÄÑÒÔµÖ´ïÍêÈ«ÏûÈÚ£¬£¬Êǵ¼ÖÂÖ×Áö¸´·¢Ï£ÍûµÄÖ÷ÒªÔ­Òò¡£¡£ÓëÍâ¿ÆÊÖÊõÇгý²î±ðµÄÊÇ£¬£¬RFAÊÇͨ¹ýÈÈЧӦʹÖ×Áö±¬·¢Ô­Î»Äý¹ÌÐÔ»µËÀ£¬£¬ÔÚÕâ¸öÀú³ÌÖУ¬£¬¿É´Ù·¢´ó×ÚÖ×ÁöÏà¹Ø¿¹Ô­ÊÍ·Å£¬£¬ÓÕµ¼»úÌ屬·¢¿¹Ö×ÁöÃâÒßЧӦ¡£¡£È»¶ø£¬£¬Ð»ÏþÑà½ÌÊÚÍŶÓÔÚ¶àÄêÖ×ÁöÏûÈÚµÄÁÙ´²Êµ¼ù¼°Ïà¹ØÑо¿Öз¢Ã÷£¬£¬Ö×ÁöÏûÈÚÊõºóËù±¬·¢µÄ¿¹Ö×ÁöÃâÒßЧӦȱ·¦ÒÔÒÖÖÆÊ£ÓàÖ×Áö¸´·¢£¬£¬ÇÒ²¿·Ö»¼Õß·ºÆðÖ×Áö¶ñ»¯Ï£Íû£¬£¬ÏÖÔÚÏà¹Ø»úÖÆÉÐδÃ÷È·¡£¡£

½üÄêÀ´£¬£¬³ÌÐòÐÔéæÃüÊÜÌå-1/³ÌÐòÐÔéæÃüÅäÌå-1£¨Programmed cell death protein-1/Programmed cell death ligand 1, PD-1/PD-L1£©Þ׿¹ÖÎÁÆÔÚÖ×ÁöÃâÒßÖÎÁÆÁìÓòÈ¡µÃÁËÖØ´óÍ»ÆÆ¡£¡£Ð»ÏþÑà½ÌÊÚÍŶÓÔÚ²»ÍêÈ«ÏûÈÚÖ×Áö¶¯ÎïÄ£×ÓÖз¢Ã÷£¬£¬ÏûÈÚÊõºóÊ£ÓàÖ×ÁöÍâòPD-L1ÏÔÖøÉϵ÷£¬£¬ÕâÅú×¢PD-1/PD-L1¼ÓÈëÏûÈÚÊõºóÊ£ÓàÖ×Áö±¬·¢ÃâÒßÌÓÒÝ¡£¡£È»¶ø£¬£¬»ØÊ×ÐÔÑо¿ºÍ¶¯ÎïʵÑéÊý¾Ý¾ùÅú×¢£¬£¬¼òµ¥PD-1/PD-L1Þ׿¹ÖÎÁƶÔRFAÊõºóÖ×ÁöÏ£ÍûÁÆÐ§Ç·¼Ñ¡£¡£Ñо¿ÍŶӽøÒ»²½ÆÊÎö·¢Ã÷£¬£¬RFAÊõºóÊ£ÓàÖ×ÁöSTINGͨ·¼¤»îȱ·¦£¬£¬µ¼ÖÂÊ£ÓàÖ×ÁöÖÐTÁܰÍϸ°û½þÈóÉÙ£¬£¬ÊÇPD-1/PD-L1Þ׿¹ÖÎÁƲ»¼ÑµÄ¿ÉÄÜÔ­Òò¡£¡£

¿ÉÊÇ£¬£¬ÏÖÔÚSTINGͨ·¼¤»î¼ÁºÍPD-1/PD-L1Þ׿¹¿¹ÌåÁªºÏÖÎÁÆÈÔ±£´æÄÑÌ⣺£º£ºPD-1/PD-L1Þ׿¹¿¹ÌåºÍSTINGͨ·¼¤»îÒ©ÎïµÄÁÙ´²Ó¦ÓÃÈÔÊÜÏÞÓÚÒòÒ©Îï·Ç°ÐÏòÔËË͵¼ÖµÄÃâÒßÏà¹Ø¶¾¸±×÷Óᣡ£±ðµÄ£¬£¬PD-L1¿¹Ìå¼°STING¼¤»î¼ÁµÄ×÷ÓÃλµã»®·ÖλÓÚÖ×Áöϸ°ûÍâò¼°¿¹Ô­Ìá³Êϸ°ûÄÚ£¬£¬ÐèÒªµÖ´ïÑÇϸ°û²ãÃæ¾«×¼µÝËͲſÉʵÏÖÒ©ÎïµÄÓÐÓÃЭͬ×÷Óᣡ£

Ϊ½â¾öÕâÒ»ÄÑÌ⣬£¬¸ÃÑо¿½ÓÄÉ˧ÐÄÌνÌÊÚÍŶÓÑз¢µÄÉúÎïÏàÈÝÐÔµÄÁ×Ö¬ÖÊÁϼ°ÆäÍŶÓÖÆ±¸µÄÒ»ÖÖpHºÍMMP-2Ë«ÖØÃô¸ÐµÄÄÉÃ×ÄÒÅÝ£¬£¬ÊµÏÖÁËÑÇϸ°ûˮƽµÄ³ÌÐòÐÔ¾«×¼Ò©Îï¿ØÊÍ¡£¡£ÄÉÃ×ÄÒÅݵÄˮǻ°ü¹üSTING¼¤»î¼Á£¬£¬±í²ãͨ¹ýMMP-2Ãô¸ÐµÄ¶ÌëÄPLGVRGżÁª¿¹PD-L1¿¹Ìå¡£¡£Í¬Ê±£¬£¬Í¨¹ýËáÃô¸ÐµÄõ£°·¼üżÁªPEG£¬£¬¿É×è°­¿¹PD-L1¿¹ÌåÓëPD-L1ÑôÐÔµÄÕý³£×éÖ¯Á¬Ïµ£¬£¬´Ó¶ø¸³ÓèÁËÄÉÃ×Ò©ÎïµÄÒþÉíÐÔÄÜ¡£¡£µ±ÄÉÃ×Ò©Î︻¼¯ÔÚÖ×Áö×éÖ¯Öк󣬣¬PEG¿Ç²ãºÍ¿¹Ìå»®·ÖÔÚÊ£ÓàÖ×Áö΢ÇéÐεÄËáÐÔÌõ¼þºÍMMP-2µÄ´¥·¢ÏϹ½ÁÎÊÍ·Å¡£¡£¶øPEGºÍ¿¹ÌåµÄÊÍ·ÅʹµÃÄÒÅݵÄÍâòµçλ´Ó¸ºµçÐÔ·­×ªÎªÕýµçÐÔ£¬£¬Ôö½øÁËÔØSTING¼¤»î¼ÁÄÒÅݱ»¿¹Ô­Ìá³Êϸ°ûÄÚÍÌ£¬£¬Ê¹µÃSTING¼¤»î¼ÁÔÚ°ûÖÊÓÐÓü¤»îSTINGͨ·¡£¡£ÌåÍâºÍºÉÁöСÊóµÄʵÑéÊý¾Ý¾ùÅú×¢£¬£¬¸Ãϵͳ¿Éͨ¹ý¼¤»îÊ÷ͻ״ϸ°û£¬£¬ÔöÌí¿¹Ö×ÁöTÁܰÍϸ°ûµÄÁöÄÚ½þÈ󣬣¬´Ó¶øÏÔÖøÒÖÖÆRFAÊõºóÊ£ÓàÖ×ÁöµÄÏ£Íû¡£¡£±ðµÄ£¬£¬Óë·ÇPEGÆÁÕϵÄÄÉÃ×Ò©Îï×éÏà±È£¬£¬PEGÆÁÕϲãÏÔÖø½µµÍÁËSTING¼¤»î¼ÁºÍ¿¹PD-L1¿¹ÌåÖÎÁƵ¼ÖµĸÎÔà¶¾ÐÔ¡£¡£

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

MMP-2/pHË«Ãô¸ÐÖ¬ÖÊÌå¹²ÔØSTING¼¤»î¼ÁºÍ¿¹PD-L1¿¹ÌåЭͬ¼¤»îÉ䯵ÏûÈÚÊõºó¿¹Ö×ÁöÃâÒߣ¬£¬ÒÖÖÆÊ£ÓàÖ×ÁöÏ£ÍûºÍ¸´·¢

¸ÃÑо¿Êܵ½¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÖØ´óÑо¿ÍýÏëÏîÄ¿¡¢¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÃæÉÏÏîÄ¿¡¢¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÇàÄêÏîÄ¿¼°¹ãÖÝÊÐÖØµãÁìÓòÑз¢ÍýÏëÏîÄ¿µÈ×ÊÖú¡£¡£ÂÛÎÄÎÊÌâΪ¡°Nanodrug shows spatiotemporally controlled release of anti-PD-L1 antibody and STING agonist to effectively inhibit tumor progression after radiofrequency ablation¡±¡£¡£ngµç×ÓÓÎÏ·Á¥ÊôµÚһҽԺΪÂÛÎĵÚÒ»µ¥Î»¼°Í¨Ñ¶µ¥Î»£¬£¬Ð»ÏþÑà½ÌÊÚ¡¢Ë§ÐÄÌνÌÊÚ¡¢ÐìÃ÷¸±½ÌÊÚ¼°ÕÅ´ºÑô¸±Ñо¿Ô±ÎªÅäºÏͨѶ×÷Õߣ¬£¬ngµç×ÓÓÎÏ·Á¥ÊôµÚÒ»Ò½Ôº²©Ê¿ºó¹ù»ÀÁá¡¢ngµç×ÓÓÎÏ·Á¥ÊôµÚÆßÒ½ÔºÖúÀíÑо¿Ô±»Æ½ðÉú¼°ngµç×ÓÓÎÏ·Á¥ÊôµÚÒ»Ò½ÔºÖúÀíÑо¿Ô±Ì·ÑóΪÅäºÏµÚÒ»×÷Õß¡£¡£

ÂÛÎÄÁ´½Ó£º£º£ºhttps://www.sciencedirect.com/science/article/pii/S1748013222000524

¡¾ÍøÕ¾µØÍ¼¡¿